Key facts
- This page summarizes TPAV, LLC's Form 4 filing for Traws Pharma, Inc. (TRAW).
- 2 reported transactions and 2 derivative rows are listed below.
- Accepted by SEC: 27 Jan 2025, 19:01.
TPAV, LLC - 29 Dec 2024 Form 4 Insider Report for Traws Pharma, Inc. (TRAW)
- Reporting relationship
- 10%+ Owner
- Issuer ticker
- TRAW
- Reported as of
- 29 Dec 2024
- Net transaction value
- $0
- SEC form
- 4
- Accepted by SEC
- 27 Jan 2025, 19:01:45 UTC
- Prior SEC filing
- 03 Apr 2024
- Next SEC filing
- 08 Apr 2025
- Source filing
- View source filing
- Reporting owner signature
- /s/ TPAV, LLC, By: Nikolay Savchuk, Manager
Source evidence
Original filing metadata and source links for verification.
5 source fields
Reporting owner
1 detail
Key filing fact
TPAV, LLC filed Form 4 for Traws Pharma, Inc. (TRAW) on 27 Jan 2025.
Change
- Previous filing in this sequence was filed on 03 Apr 2024.
- Current net transaction value: $0.
Research use
- This tells you what this filing adds before you inspect full transaction and derivative tables.
- You can trace every row back to the original SEC filing document.
Evidence
Filed on Form 4
View source filing
Ownership activity is grounded in SEC Form 4 disclosures.
Reported derivative securities
Options, warrants, convertible securities, or similar derivative positions disclosed in the filing.
TRAW
transaction
Derivative
Pre-Funded Warrant (right to buy)
Purchase
- Transaction value
- Shares
- +96,348
- Change %
- Price
- Shares after
- 96,348
- Date
- 29 Dec 2024
- Ownership
- Direct
- Underlying class
- Common Stock
- Underlying amount
- 96,348
- Exercise price
- $0.0100
- Footnotes
- F1, F2, F3
TRAW
transaction
Derivative
Series A Warrant (right to buy)
Purchase
- Transaction value
- Shares
- +96,348
- Change %
- Price
- Shares after
- 96,348
- Date
- 29 Dec 2024
- Ownership
- Direct
- Underlying class
- Common Stock
- Underlying amount
- 96,348
- Exercise price
- $13.42
- Footnotes
- F3, F4, F5
* marks a reported price that did not pass the local price check.
Additional SEC filing notes
Filing notes and footnotes
Explanation of responses 5 footnotes
Footnote F1
The Pre-Funded Warrants shall become exercisable upon stockholder approval of the exercise of the Pre-Funded Warrants, in accordance with Nasdaq listing rules.
Footnote F2
The Pre-Funded Warrants do not expire.
Footnote F3
The Pre-Funded Warrants and Series A Warrants were purchased as part of Class B Units, with each Class B Unit consisting of one Pre-Funded Warrant and one Series A Warrant, at a purchase price of $5.093 per Class B Unit.
Footnote F4
The Series A Warrants shall become exercisable on June 30, 2025; provided however, that the Series A Warrants may not be exercised prior to the issuer's receipt of stockholder approval of the exercise of the Series A Warrants, in accordance with Nasdaq listing rules.
Footnote F5
The Series A Warrants shall expire on the date that is the earlier of (a) December 31, 2029, and (b) subject to the fulfilment of certain equity conditions, thirty trading days after the last of the following data readouts to occur, as announced by the issuer: (i) Ferret animal model Bird Flu data, (ii) non-human primate Bird Flu data, or (iii) Phase 2a Influenza A human clinical data.